Genentech, Inc.

Genetech, Inc.

Gordon A Vehar

David V Goeddel

William J Kohr

Diane Pennica

Richard M Lawn

Arthur D Levinson

William I Wood

Herbert L Heyneker

Daniel J Capon

Christian C Simonsen

Elizabeth M Yelverton

Donogh P O'Brien

Soumitra Roy

Karen L Wion

Nicholas F Paoni

William F Bennett

William E Holmes

Michael Blaber

Josiah N Wilcox

A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild-type DHFR with methotrexate.

Human tPA production using vectors coding for DHFR protein

DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.

Methods and Deoxyribonucleic acid for the preparation of tissue factor protein

Methods and deoxyribonucleic acid for the preparation of tissue factor protein

The present invention related to a method and therapeutic composition for the treatment of coagulation disorders comprising administration of a lipoprotein associated coagulation inhibitor.

Methods for the treatment of coagulation disorders with lipoprotein associated coagulation inhibitor (LACI)

Human tissue plasminogen activator (t-PA) is produced in useful quantities using recombinant DNA techniques. The invention disclosed thus enables the production of t-PA free of contaminants with which it is ordinarily associated in its native cellular environment. Methods, expression vehicles and various host cells useful in its production are also disclosed.

Human tissue plasminogen activators

Method of treatment using recombinant human tissue plasminogen activator

The present invention relates to a method and therapeutic composition for the treatment of myocardial infarction comprising administration of a tissue factor protein antagonist and a thrombolytic agent. In addition, the present invention relates to methods of neutralizing coagulation, including in patients with deep vein thrombosis, with anti-tissue factor antibodies.

Methods of neutralizing coagulation with anti-tissue factor antibodies

A method for producing tissue plasminogen activator (t-PA) in eukaryotic host cells is disclosed. Enhanced levels of t-PA production are obtained by co-amplification of the t-PA gene through treatment of cultures transformed with mutant or wild type DHFR with methotrexate.

Tissue plasminogen activators (t-PAs) and derivatives thereof are produced in useful quantities using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and amino acid substitution derivatives. A deletion derivative lacking the N-terminal first 68 amino acids is specifically exemplified having requisite t-PA characteristics. The invention disclosed thus enables the production of t-PAs and derivatives thereof via recombinant means. Methods, expression vehicles and various host cells useful in the production of said t-PAs and derivatives thereof are also disclosed.

Tissue plasminogen activators and derivatives thereof as produced by

The invention concerns a method for inhibiting the growth and/or causing regression of tumors by administering a therapeutically effective dose of a procoagulant and a cytokine, preferably TNF-.beta., TNF-.alpha. and/or IL-1. In a specific aspect, the invention concerns a method for tumor treatment by the administration of a therapeutically effective amount of a thrombomodulin inhibitor and a cytokine. The invention also concerns thrombomodulin inhibitors and pharmaceutical compositions used in the course of these treatments.

Compositions and methods for the treatment of tumors

The invention concerns a method for inducing a selective collapse of the vasculature of a solid tumor by administering to a patient a therapeutically effective dose of a combination of a compound preventing the formation of a functional thrombin-thrombomodulin complex and a cytokine selected from the group of TNF-.beta. (LT), TNF-.alpha., IL-1, and IFN-.gamma.. The invention further concerns the composition used in this method.

Composition and methods for the treatment of tumors

Tissue plasminogen activator (t-PA) derivatives are produced in useful quantities using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and amino acid substitution derivatives. A deletion derivative lacking the N-terminal first 68 amino acids is specifically exemplified having requisite t-PA characteristics. The invention disclosed thus enables the production of t-PA derivatives via recombinant means. Methods, expression vehicles and various host cells useful in the production of said t-PA derivatives are also disclosed.

Methods of preparing tissue plasiminogen activator derivative composition

Biologically active variant tissue plasminogen activators are disclosed. The disclosure focuses on position 276 variants that exhibit enhanced fibrin specificity.

Growing community of inventors

San Carlos, CA, United States of America

Gordon A Vehar